The Boston-based T1D Fund is launching a $150 million fundraising campaign and making a strategic shift in how it invests ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Food and Drug Administration on Wednesday said it is aiming to reduce the number of human clinical studies required for ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Hong Kong Exchanges and Clearing (HKEX) will launch five new weekly stock options and a Hang Seng Biotech Index Futures contract this month, expanding hedging tools for investors as derivatives ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...